Remus PharmaLong consolidation and small consolidation at resistance gives a small stop keeping in watch
50.75 INR
215.37 M INR
2.12 B INR
1.87 M
About REMUS PHARMACEUTICALS L
Sector
CEO
Arpit Deepakkumar Shah
Headquarters
Ahmedabad
Website
Founded
2015
ISIN
INE0O5T01011
FIGI
BBG01GNDCR97
Remus Pharmaceuticals Ltd. operates as a pharmaceutical company. It is engaged in the pharmaceutical business involving marketing, trading and distribution through third party of wide range of pharmaceutical formulations and products manufactured under loan license on contract manufacturing in India as well as in foreign countries. The company was founded by Arpit Deepakkumar Shah and Roma Vinodbhai Shah on September 21, 2015 and is headquartered in Ahmedabad, India.
ATH Breakout - REMUS PHARMAPlease look into the chart for a detailed understanding.
Consider these for short-term & swing trades with 2% profit.
For BTST trades consider booking
target for 1%-2%
For long-term trades look out for resistance drawn above closing.
Please consider these ideas for educational purpose
Please n
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of REMUS is 2,542.90 INR — it has decreased by −0.46% in the past 24 hours. Watch REMUS PHARMACEUTICALS L stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange REMUS PHARMACEUTICALS L stocks are traded under the ticker REMUS.
REMUS stock has fallen by −3.10% compared to the previous week, the month change is a 2.67% rise, over the last year REMUS PHARMACEUTICALS L has showed a 81.80% increase.
REMUS reached its all-time high on Sep 3, 2024 with the price of 2,834.75 INR, and its all-time low was 427.80 INR and was reached on May 29, 2023. View more price dynamics on REMUS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track REMUS PHARMACEUTICALS L financials in yearly and quarterly reports right on TradingView.
REMUS net income for the last half-year is 140.11 M INR, while the previous report showed 158.89 M INR of net income which accounts for −11.82% change. Track more REMUS PHARMACEUTICALS L financial stats to get the full picture.
As of Dec 13, 2024, the company has 48.00 employees. See our rating of the largest employees — is REMUS PHARMACEUTICALS L on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REMUS PHARMACEUTICALS L EBITDA is 390.50 M INR, and current EBITDA margin is 13.38%. See more stats in REMUS PHARMACEUTICALS L financial statements.
Like other stocks, REMUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REMUS PHARMACEUTICALS L stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REMUS PHARMACEUTICALS L technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REMUS PHARMACEUTICALS L stock shows the buy signal. See more of REMUS PHARMACEUTICALS L technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.